Mary Lor
About Mary Lor
Mary Lor is a Senior Pharmacokinetic Scientist II in Clinical Pharmacology at Celerion, where she has worked since 2013. She has a background in ecotoxicology and biology, and she plays a key role in generating reports and reviewing clinical data for pharmacokinetic studies.
Work at Celerion
Mary Lor holds the position of Senior Pharmacokinetic Scientist II in Clinical Pharmacology at Celerion, a role she has maintained since 2013. In this capacity, she plays a central role in generating reports and reviewing clinical and analytical data for pharmacokinetic studies. Her responsibilities include interacting with government regulatory agencies and clients to design pharmacokinetic studies. She also engages in scientific discussions with sponsors and serves as the key scientific contact for informed decision-making.
Education and Expertise
Mary Lor has a solid educational background in the sciences. She earned a Graduate Diploma in Ecotoxicology from Concordia University, where she studied from 1994 to 1995. Prior to that, she completed her Bachelor of Science in Biology at the same institution from 1992 to 1994. Her foundational education includes a Diploma of College Studies in Health Science from Vanier College, achieved between 1989 and 1991. This educational path has equipped her with expertise in pharmacokinetics and clinical pharmacology.
Background
Mary Lor began her career as a Laboratory Technician at Health Canada in 1996, where she worked for six months in Ottawa, Ontario. This early experience provided her with a practical understanding of laboratory operations and regulatory standards. Since then, she has developed her career in pharmacokinetics, focusing on clinical studies and data analysis.
Achievements in Pharmacokinetics
In her role as a Senior Pharmacokinetic Scientist II, Mary Lor utilizes a variety of pharmacokinetic modeling tools, including ADAPT-II, ADAPT5, IT2S, NONMEM, S-ADAPT, XPOSE, WinNonlin, and Phoenix WNL. She has experience with various study types, such as impairment studies, QTc studies, special population studies, first in human studies, and bioequivalence studies. Her involvement in these diverse projects highlights her comprehensive skill set in the field.